Avanti Therapeutics is commercializing a portfolio of protein-based products – recombinant proteins and peptides – for the prevention and treatment of hospital acquired – infections. The company has focused its initial efforts on developing products for the prevention and treatment of staphylococcal infections.



The cost of infections from antibiotic-resistant bacteria in the United States is in excess of $4 billion annually. With the rise in antibiotic resistance and increased infection rates, a great burden has been placed on the care of the immuno-compromised, such as premature newborns, cancer patients, transplant patients, and diabetics. Due to the rise in antibiotic resistance, current treatments and products are becoming less effective against, and creating more resistant strains of, hospital infections.
 
AT-GC has developed a portfolio of products for commercialization for the prevention and treatment of multi-drug resistant staphylococcal infections. AT-GC currently has two products in pre-clinical development-Staphcin and ATGC-S409. Staphcin has demonstrated the efficacy in eradicating Methicillin resistant S. aureus as well as Methicillin-susceptible S. aureus biofilms on artificial surfaces. Staphcin is one of the very few anti-infective product that is able to both rapidly kill staphylococci (Staph) and eliminate staph biofilms.
 
All the products have undergone extensive pre-clinical research with excellent results. We expect the products to be in clinical trials by 2^nd quarter of 2006.

 Microbial Infection

 Hospital infection

 Bio defense Applications

Staphcin^TM

Sraphcin, an endopeptidase specific for the cell wall peptidoglycan of staphylococci, is an extremely potent anti-staphylococcal agent.

Staphcin is used as a research and diagnostic tool. Because it lyses staphylococci efficiently, it is widely used when preparing staphylococcal DNA or other cellular components for genetic and biochemical studies and for the preparation of protoplasts for transformation. Preparation and analysis of bacterial DNA has become a powerful tool used by clinical and other microbiologists in epidemiological studies aimed at tracing sources of infection or bacterial contamination.

AT-GC has been producing Staphcin of greater than 90% purity under the trade name AMBICIN® L since 1991. Staphcin is a highly purified recombinant protein, and is an essential tool for studying the epidemiology and molecular genetics of staphylococci. Staphcin is the most cost-effective endopeptidase available for staphylococcal infection studies.

Uses of Staphcin

      1.                  Research & Diagnostics

2.                  Hospital and medical establishment applications

3.                  consumer applications